Dr Reddy’s and Immutep confirmed that the TACTI-004 Phase III trial will be discontinued after the IDMC’s interim futility analysis. The decision halts enrolment and winds down the study, reflecting the trial’s limited potential to achieve efficacy goals. Both companies emphasized their commitment to ongoing oncology research programs.
Introduction To The Announcement
On March 13, 2026, Dr Reddy’s Laboratories Ltd disclosed that Immutep, its partner in the TACTI-004 trial, will halt enrolment and wind down the study. The IDMC’s recommendation followed a detailed interim futility analysis.
Details Of The Trial Discontinuation
-
Trial: TACTI-004 Phase III study
-
Focus: Immuno-oncology treatment combining Immutep’s eftilagimod alpha with pembrolizumab
-
Reason: Interim futility analysis showed low probability of meeting endpoints
-
Action: Enrolment halted, study winding down
Strategic Importance
While the discontinuation marks a setback, Dr Reddy’s and Immutep emphasized their continued focus on oncology innovation. Resources will be redirected to other promising clinical programs in immunotherapy and cancer treatment.
Broader Implications
The decision underscores the importance of interim analyses in clinical trials, ensuring patient safety and efficient resource allocation. For stakeholders, it reflects transparent governance and commitment to scientific rigor.
Key Highlights
• TACTI-004 Phase III trial discontinued after futility analysis
• IDMC recommended halting enrolment and winding down study
• Combination therapy with eftilagimod alpha and pembrolizumab evaluated
• Companies to redirect focus to other oncology programs
• Decision reflects scientific rigor and patient safety priorities
Sources: Reuters, Business Standard, Immutep Corporate Release